2026 Dyslipidemia Guidelines: What NPs Need to Know

Did you hear about the new 2026 ACC/AHA dyslipidemia guidelines? Every time a major guideline update rolls out, we see the same wave of messages in our community: Do I need to relearn everything? Is this going to be on my boards? Am I already behind?

Here’s the good news (and we mean this sincerely): you are exactly where you need to be! New guidelines don’t rewrite the exam blueprint overnight—it typically takes a few years for updated guidelines to work their way into certification exam content. So if you’re deep in NP board prep right now, there is no need to panic or even pivot your study plan. This is simply your cue to understand the big picture, so you’re not caught off guard if a patient (or a preceptor) brings it up.

Let’s break down what’s actually new in the 2026 Guideline on the Management of Dyslipidemia, what stayed the same, and how to think about all of it depending on whether you’re studying for boards or already out there seeing patients.

Prefer to watch? Check out this video on the SMNP Reviews YouTube channel!

Don’t Worry: The Foundation Hasn’t Moved!

This newest update, published by the American College of Cardiology (ACC), American Heart Association (AHA), and a long list of partnering organizations, officially retired the 2018 Guideline on the Management of Blood Cholesterol. There’s a new title with some expanded scope, but the core clinical philosophy you’ve already been studying is fully intact.

Statins remain first-line therapy and LDL-C lowering is still the central goal of treatment. Risk stratification still drives how aggressively we treat. Additionally, lifestyle changes like balanced nutrition, physical activity, weight management, sleep, and tobacco cessation are still considered foundational. In fact, the 2026 dyslipidemia guidelines continue to give a heart-healthy diet a strong recommendation for reducing cardiovascular events, and notes that these lifestyle factors alone can meaningfully lower cardiovascular risk even in people with a genetic predisposition to heart disease.

So if you’ve been reviewing statin indications, ASCVD risk assessment, and lifestyle counseling in your study plan, that knowledge is not going anywhere. That’s still the “heart” of this content, for boards and for clinical practice!

The Big, New Theme: Earlier, More Individualized Prevention

Two big-picture shifts in the 2026 ACC/AHA dyslipidemia guidelines stand out:

1. A Stronger Push Toward Primary Prevention

Instead of waiting for a patient to have a cardiovascular event before treating aggressively, the guideline leans harder into identifying risk early and intervening sooner, especially across the full lifespan. Think about childhood cholesterol screening starting between ages 9 to 11 and all the way through the care of older adults. The goal is preventing that first event, not just responding after it happens.

2. More Individualized, Risk-Based Care

The 2026 guidelines put more emphasis on populations who carry disproportionate cardiovascular risk, including adults with chronic kidney disease, HIV, and diabetes (type 1 and 2). For these groups, treatment may be warranted earlier and more aggressively, sometimes regardless of a calculated risk score. That’s a meaningful shift toward genuinely personalized decision-making.

For test-taking purposes, though, the underlying logic hasn’t changed: assess risk, then let that risk level guide your treatment decisions.

The New 2026 Dyslipidemia Guidelines: The Full Breakdown

1. LDL-C Goals Are Here to Stay! (And They’re Lower)

One of the more notable changes is the return of specific LDL-C treatment targets, something the 2018 guideline had moved away from in favor of a percentage-reduction approach. The 2026 ACC/AHA dyslipidemia guidelines restore numeric goals, and for secondary prevention (like patients with established ASCVD), those goals are lower than before.

Patients considered very high risk for ASCVD events are now generally targeted to an LDL-C goal of less than 55 mg/dL, with a non-HDL-C goal of less than 85 mg/dL. A smaller subset of ASCVD patients not classified as very high risk have a slightly less aggressive goal of under 70 mg/dL. The message from the writing committee is clear and consistent: when it comes to LDL-C, lower for longer continues to show benefit.

The clinical takeaway here is simple: know your patient’s risk category, and treat to the specific numeric goal that matches it.

2. Meet PREVENT: The New Risk Calculator

You’ve probably heard whispers about this one already, especially if you’ve been following updates in hypertension management too because the same tool has been showing up across multiple specialty guidelines. The 2026 dyslipidemia guidelines officially adopt the AHA’s PREVENT equations in place of the older Pooled Cohort Equations for estimating cardiovascular risk in primary prevention for adults ages 30 to 79.

What makes PREVENT a little different? It estimates both 10-year and 30-year cardiovascular risk, and it incorporates additional variables like kidney function (eGFR) and statin use, with optional inputs like HbA1c and social risk factors such as smoking history and even the patient’s ZIP code). It’s a more contemporary, more nuanced tool.

The reassuring part for board prep is that the underlying skill you’re being tested on doesn’t change. You still need to know how to calculate and interpret an ASCVD risk percentage, and you still need to know what that percentage means for your treatment decision. The tool’s name may be new, but the thinking behind it (use a validated risk calculator to guide who gets treated and how aggressively) is the same clinical reasoning you’ve already been practicing.

3. What is Lipoprotein(a)?

If lipoprotein(a), or Lp(a), hasn’t been on your radar yet, it’s about to be. Think of it as a genetically inherited, LDL-like particle that promotes plaque formation in blood vessels and is independent of a patient’s standard lipid panel. That means someone can have a totally normal-looking cholesterol panel and still be carrying significant hidden cardiovascular risk because of an elevated Lp(a).

The 2026 dyslipidemia guidelines now recommend that every adult have their Lp(a) checked at least once in their lifetime. An elevated result doesn’t come with its own separate treatment yet, but it does function as a risk-enhancing factor.

4. Coronary Artery Calcium Scoring

The guideline continues to support the use of coronary artery calcium (CAC) scoring, which is a CT scan that detects actual calcium buildup in the coronary arteries and shows clinicians whether atherosclerotic plaque already exists. For a patient who is borderline on the need to start a statin, a higher CAC score can be the tiebreaker that supports starting therapy, while a very low or zero score may support a more conservative, watch-and-wait approach in select patients.

5. New Medication Options

The 2026 dyslipidemia guidelines also reflect an expanded pharmacologic landscape, incorporating newer FDA-approved lipid-lowering therapies alongside familiar options like ezetimibe (Zetia), bempedoic acid, and PCSK9 monoclonal antibodies for patients who don’t reach goal on statin therapy alone.

For boards, the core hierarchy for management is unchanged: statins first, add nonstatin therapy when goals aren’t met despite maximally tolerated statin dosing.

How Should NPs Use the New 2026 Dyslipidemia Guidelines?

📖 If you’re studying for boards: stay the course! You still need to be rock solid on ASCVD risk assessment, LDL-C thresholds, and knowing exactly when to start a statin. Certification exams are not going to test you on brand-new nuance that hasn’t been fully absorbed into clinical practice yet. Trust your current study plan.

🩺 If you’re already in clinical practice: this is where these updates genuinely earn their keep. Lower LDL-C targets, routine Lp(a) screening, the PREVENT calculator, and an expanded medication list all give you more precision and more flexibility to tailor care to the patient sitting in front of you.

Either way, the big-picture reassurance we want you to walk away with is that lipid management hasn’t been reinvented. It’s been refined. We’re identifying risk earlier, individualizing care more thoughtfully, and layering in additional tools to guide decision-making.

You’ve got this! Keep showing up for your studies, keep showing up for your patients, and trust that the foundation you’re building is built to last.

Further Reading

For further reading, check out the full guidelines here. Or, the Journal of the American College of Cardiology (JACC) has a helpful article “2026 Dyslipidemia Guidelines-at-a-Glance” that provides a great summary.

And for more (free!) tips for NPs studying for boards, check out these other posts on the blog:

• Am I Ready to Take My NP Board Exam?
• Test-Taking Strategies: How to Conquer NP Board Exam Anxiety!
• How to Create Your NP Boards Study Schedule

Note: Any and all references to trademarks or registered companies are for educational purposes only and are not inclusive of all possible names. Blueprint Test Preparation is in no way endorsing or promoting any product in these educational materials.